Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 16
- Registration Number
- NCT04062448
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-Ku, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Tachikawa, Japan
🇯🇵Osaka Metropolitan University Hospital, Osaka, Japan
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04043845
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04042376
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, China
🇨🇳The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
Biomarker Guided Treatment in DLBCL
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT04025593
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04016805
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03964090
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT03960840
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03949062
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Kerry Rogers
- Registration Number
- NCT03943342
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03939182
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.